 Approval Package for:

APPLICATION NUMBER:

15-034 / S-032

Trade Name: Ponstel

Generic Name: mefenamic acid capsules

Sponsor: Parke Davis

Approval Date: April 23, 1998
### CONTENTS

#### Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Reviews / Information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Approvable Letter</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/ Biopharmaceutics Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td></td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:

15-034 / S-032

APPROVAL LETTER
Parke-Davis
Attention: James A. Parker, Jr.
Worldwide Regulatory Affairs
201 Tabor Road
Morris Plains, NJ 07950

Dear Mr. Parker, Jr.:

Please refer to your January 19, 1998 supplemental new drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Ponstel® (mefenamic acid capsules) 250mg.

These supplemental application provide for revised draft labeling for the Ponstel® package insert identical to the proposed NSAID Package Insert Labeling Template. We remind you at the next printing to include the following editorial changes:

- Line 76, “Special Populations” section, Pediatric: the tradename should be initially referenced.
- Lines 121-123, as proposed by Sponsor, two contraindications from current labeling were retained.
- Line 224, “Precautions” section, Renal Effects, the tradename should be referenced.
- Line 315-321, as proposed by Sponsor, retained from current labeling.
- Line 334, “Drug Interactions” Furosemide, the tradename should be referenced.
- Line 346, “If NSAIDs are administered. . .” should be re-worded to “During concomitant therapy with NSAIDs. . .”.
- Lines 357-364, As proposed by Sponsor, added Antacids and compounds that inhibit CYP2C9 to the “Drug Interaction” subsection.

We have completed the review of this supplemental application, including the submitted draft labeling, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the draft labeling submitted on January 19, 1998. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed draft labeling. Marketing the product with FPL that is not identical to this draft labeling may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material.

For administrative purposes, this submission should be designated “FINAL PRINTED LABELING” for approved NDA 15-034. Approval of this submission by FDA is not required before the labeling is used.
If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required. Additionally, we remind you of our request to conform to the NSAID class labeling template of December 20, 1996.

If you have any questions, please contact D’Annie Gunter, P.D., Project Manager, (301) 827-2090.

Sincerely,

Michael Weintraub, M.D.
Office Director
Division of Anti-Inflammatory, Analgesic, and Ophthalmic Drug Products, HFD-550
Office of Drug Evaluation V
Center for Drug Evaluation and Research

MW 4/23/98
NDA 15-034/S-032

cc:
NDA 15-034
Div. files
HF-2/Med Watch (with draft labeling)
HFD-613/OGD (with draft labeling)
HFD-40/ DDMAC (with draft labeling)
HFA-100
HFD-830/Chen
DISTRICT OFFICE
HFD-80
HFD-550/Gunter
HFD-550/Koerner
HFD-550/Yaciw/Patel

saved as n: 15034s32.ltr

APPROVAL (AP)
APPLICATION NUMBER:

15-034 / S- 032

LABELING
Ponstel®
(Mefenamic Acid)

DESCRIPTION
Ponstel (mefenamic acid) is N-(2,3-xylyl)-anthranilic acid. It is an analgesic agent for oral administration. Ponstel is available in capsules containing 250 mg of mefenamic acid. Each capsule also contains lactose, NF. The capsule shell and/or band contains cellulose acetate, USP; D&C yellow No. 10; FD&C blue No. 1; FD&C red No. 3; FD&C yellow No. 6; gelatin, NF; glycerol monostearate; silicic acid; sodium benzoate, NF; sodium lauryl sulfate, NF; titanium dioxide, USP.

It is a white powder with a melting point of 230°–231°C, molecular weight 241.29, and water solubility of 0.004% at pH 7.1.

CLINICAL PHARMACOLOGY
Ponstel is a nonsteroidal agent with demonstrated antiinflammatory, antipyretic, and analgesic activity in laboratory animals. The mode of action is not known. In clinical trials, Ponstel was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site.

Pharmacologic studies show Ponstel does not relieve morphine abstinence signs in abstinent, morphine-habituated monkeys. Following a single 1-gram oral dose, peak plasma levels of 10 µg/mL occurred in 2 to 4 hours with a half-life of 2 hours. Following multiple doses, plasma levels are proportional to dose with no evidence of drug accumulation. One gram of Ponstel given four times daily produces peak blood levels of 20 µg/mL by the second day of administration.

Following a single dose, sixty-seven percent of the total dose is excreted in the urine as unchanged drug or as one of two metabolites. Twenty to twenty-five percent of the dose is excreted in the feces during the first three days.

In controlled, double-blind, clinical trials, Ponstel was evaluated for the treatment of primary spasmodic dysmenorrhea. The parameters used in determining efficacy included pain assessment by both patient and investigator, the need for concurrent anesthetic medication, and evaluation of change in frequency and severity of symptoms characteristic of spasmodic dysmenorrhea. Patients received either Ponstel, 500 mg (2 capsules) as an initial dose and 250 mg every 6 hours, or placebo at onset of bleeding or of pain, whichever began first. After three menstrual cycles, patients were crossed over to the alternate treatment for an additional three cycles. Ponstel was significantly superior to placebo in all parameters, and both treatments (drug and placebo) were equally tolerated.

INDICATIONS AND USAGE
Ponstel is indicated for the relief of moderate pain when therapy will not exceed one week. Ponstel is also indicated for the treatment of primary dysmenorrhea.

Studies in children under 14 years of age have been inadequate to evaluate the safety and effectiveness of Ponstel.

CONTRAINDICATIONS
Ponstel should not be used in patients who have previously exhibited hypersensitivity to it.

Because the potential exists for cross-sensitivity to aspirin or other nonsteroidal antiinflammatory drugs, Ponstel should not be given to patients in whom these drugs induce symptoms of bronchospasm, urticaria, or angioedema.

Ponstel is contraindicated in patients with active ulceration or chronic inflammation of either the upper or lower gastrointestinal tract.

Ponstel should be avoided in patients with preexisting renal disease.

WARNINGS
If diarrhea occurs, the dosage should be reduced or temporarily suspended (see ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION). Certain patients who develop diarrhea may be unable to tolerate the drug because of recurrence of the symptoms on subsequent exposure.

Ponstel (Mefenamic Acid)

Risk of GI Ulceration, Bleeding and Perforation with NSAID Therapy: Serious gastrointestinal toxicity, such as bleeding, ulceration, and perforation, can occur at any time, with or without warning symptoms, in patients treated chronically with NSAID therapy. Although minor upper gastrointestinal problems, such as dyspepsia, are common, usually developing early in therapy, physicians should remain alert for ulceration and bleeding in patients treated chronically with NSAIDs even in the absence of previous GI tract symptoms. In patients observed in clinical trials of several months to two years duration, symptomatic upper GI ulcers, gross bleeding, or perforation appear to occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. Physicians should inform patients about the signs and symptoms of serious GI toxicity and what steps to take if they occur.

Studies to date have not identified any subset of patients not at risk of developing peptic ulceration and bleeding. Except for a prior history of serious GI events and other risk factors known to be associated with peptic ulcer disease, such as alcoholism, smoking, etc., no risk factors (eg, age, sex) have been associated with increased risk. Elderly or debilitated patients seem to tolerate administration of an NSAID less well than younger individuals and most spontaneous reports of fatal GI events are in this population. Studies to date are inconclusive concerning the relative risk of various NSAIDs in causing such reactions. High doses of any NSAID probably carry less risk. However, although controlled clinical trials showing this do not exist in most cases, in considering the use of relatively large doses (within the recommended dosage range), sufficient benefit should be anticipated to offset the potential increased risk of GI toxicity.

PRECAUTIONS
If rash occurs, administration of the drug should be stopped. A false-positive reaction for urinary bile, using the diazo tablet test, may result after mefenamic acid administration. If bilirubin is suspected, other diagnostic procedures, such as the Harrison spot test, should be performed.

Renal Effects: As with other nonsteroidal antiinflammatory drugs, long-term administration of mefenamic acid to animals has resulted in renal papillary necrosis and other abnormalities in renal pathology. In humans, there have been reports of acute interstitial nephritis with hematuria, proteinuria, and occasionally nephrotic syndrome. A second form of renal toxicity has been seen in patients with preexisting conditions leading to a reduction in renal blood flow or blood volume, where the renal prostaglandins have a support role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-independent reduction in prostaglandin formation and may precipitate overt renal compensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, or those taking diuretics, and most spontaneous reports of NSAID therapy is typically followed by recovery to the pre-treatment state.

Since Ponstel is eliminated primarily by the kidneys, the drug should not be administered to patients with significantly impaired renal functions.

As with other nonsteroidal antiinflammatory drugs, borderline elevations of one or more liver tests may occur in some patients. These abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy. The SGPT (ALT) test is probably the most sensitive indicator of liver dysfunction. Serum transaminase elevations of one or more times the upper limit of normal (ULN) of SGPT or SGOT (AST) have occurred in controlled clinical trials in less than 1% of patients. A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of more severe hepatic reaction while on therapy with Ponstel. Severe hepatic reactions, including jaundice and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of more severe hepatic reaction while on therapy with Ponstel. Severe hepatic reactions, including jaundice and cases of fatal hepatitis, have been reported with other nonsteroidal antiinflammatory drugs. Although such reactions are rare, if abnormal liver tests persist or worsen, if clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (eg, eosinophilia, rash, etc.), Ponstel should be discontinued.
Ponstel (Mefenamic Acid)

Information for Patients: Patients should be advised that if rash, diarrhea or other digestive problems arise, they should stop the drug and consult their physician.

Patients in whom aspirin or other nonsteroidal antiinflammatory drugs induce symptoms of bronchospasm, allergic rhinitis, or urticaria should be made aware that the potential exists for cross-sensitivity to Ponstel.

The long-term effects, if any, of intermittent Ponstel therapy for dysmenorrhea are not known. Women on such therapy should consult their physician if they should decide to become pregnant.

Ponstel, like other drugs of its class, is not free of side effects. The side effects of these drugs can cause discomfort and, rarely, there are more serious side effects, such as gastrointestinal bleeding, which may result in hospitalization and even fatal outcomes.

NSAIDs (nonsteroidal antiinflammatory drugs) are often essential agents in the management of arthritis and have a major role in the treatment of pain, but they also may be commonly employed for conditions which are less serious.

Physicians may wish to discuss with their patients the potential risks (see WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS sections) and likely benefits of NSAID treatment, particularly when the drugs are used for less serious conditions where treatment without NSAIDs may represent an acceptable alternative to both the patient and physician.

Laboratory Tests: Because serious GI tract ulceration and bleeding can occur without warning symptoms, physicians should follow chronically treated patients for the signs and symptoms of ulceration and bleeding and should inform them of the importance of this follow-up (see Risk of GI Ulcerations, Bleeding and Perforation with NSAID Therapy).

Drug Interactions: Ponstel may prolong prothrombin time. Therefore, when the drug is administered to patients receiving oral anticoagulant drugs, frequent monitoring of prothrombin time is necessary.

Use in Pregnancy: Pregnancy Category C. Reproduction studies have been performed in rats, rabbits and dogs. Rats given up to 10 times the human dose showed decreased fertility, delay in parturition, and a decreased rate of survival to weaning. Rabbits at 2.5 times the human dose showed an increase in the number of resorptions. There were no fetal anomalies observed in these studies nor in dogs at up to 10 times the human dose.

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used only if clearly needed.

The use of Ponstel in late pregnancy is not recommended because of the effects on the fetal cardiovascular system of drugs of this class.

Nursing Mothers: Trace amounts of Ponstel may be present in breast milk and transmitted to the nursing infant; thus Ponstel should not be taken by the nursing mother because of the effects on the infant cardiovascular system of drugs of this class.

Use in Children: Safety and effectiveness in children below the age of 14 have not been established.

ADVERSE REACTIONS

Gastrointestinal: The most frequently reported adverse reactions associated with the use of Ponstel involve the gastrointestinal tract. In controlled studies for up to eight months, the following disturbances were reported in decreasing order of frequency: diarrhea (approximately 5% of patients), nausea with or without vomiting, other gastrointestinal symptoms, and abdominal pain.

In certain patients, the diarrhea was of sufficient severity to require discontinuation of medication. The occurrence of diarrhea is usually dose related, generally subsides on reduction of dosage, and rapidly disappears on termination of therapy. Other gastrointestinal reactions less frequently reported were anorexia, pyrosis, flatulence, and constipation.

Gastrointestinal ulceration with and without hemorrhage has been reported.

Hematopoietic: Cases of autoimmune hemolytic anemia have been associated with the continuous administration of Ponstel for 12 months or longer. In such cases the Coombs test results may be negative or positive. Reversal of the positive test has been noted.

Laboratory Tests: Because serious GI tract ulceration and bleeding can occur without warning symptoms, physicians should follow chronically treated patients for the signs and symptoms of ulceration and bleeding and should inform them of the importance of this follow-up (see Risk of GI Ulcerations, Bleeding and Perforation with NSAID Therapy).

Drug Interactions: Ponstel may prolong prothrombin time.

Use in Pregnancy: Pregnancy Category C. Reproduction studies have been performed in rats, rabbits and dogs. Rats given up to 10 times the human dose showed decreased fertility, delay in parturition, and a decreased rate of survival to weaning. Rabbits at 2.5 times the human dose showed an increase in the number of resorptions. There were no fetal anomalies observed in these studies nor in dogs at up to 10 times the human dose.

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used only if clearly needed.

The use of Ponstel in late pregnancy is not recommended because of the effects on the fetal cardiovascular system of drugs of this class.

Nursing Mothers: Trace amounts of Ponstel may be present in breast milk and transmitted to the nursing infant; thus Ponstel should not be taken by the nursing mother because of the effects on the infant cardiovascular system of drugs of this class.

Use in Children: Safety and effectiveness in children below the age of 14 have not been established.

ADVERSE REACTIONS

Gastrointestinal: The most frequently reported adverse reactions associated with the use of Ponstel involve the gastrointestinal tract. In controlled studies for up to eight months, the following disturbances were reported in decreasing order of frequency: diarrhea (approximately 5% of patients), nausea with or without vomiting, other gastrointestinal symptoms, and abdominal pain.

In certain patients, the diarrhea was of sufficient severity to require discontinuation of medication. The occurrence of diarrhea is usually dose related, generally subsides on reduction of dosage, and rapidly disappears on termination of therapy. Other gastrointestinal reactions less frequently reported were anorexia, pyrosis, flatulence, and constipation.

Gastrointestinal ulceration with and without hemorrhage has been reported.

Hematopoietic: Cases of autoimmune hemolytic anemia have been associated with the continuous administration of Ponstel for 12 months or longer. In such cases the Coombs test results may be negative or positive. Reversal of the positive test has been noted.

REFERENCES

5. Data on file, Medical Affairs Dept, Parke-Davis.

Direct Medical Inquiries to: Parke-Davis Div of Warner-Lambert Co, 201 Tabor Road Morris Plains, NJ 07950 USA

Revised May 1992


Ponstel (Mefenamic Acid)

Nervous System: Drowsiness, dizziness, nervousness, headache, blurred vision, and insomnia have been reported.

Integumentary: Urticaria, rash, and facial edema have been reported.

Renal: As with other nonsteroidal antiinflammatory agents, renal failure, including papillary necrosis, has been reported. In elderly patients renal failure has occurred after taking Ponstel for 2-6 weeks. The renal damage may not be completely reversible. Hematuria and dysuria have also been reported with Ponstel.

Other: Eye irritation, ear pain, perspiration, mild hepatic toxicity, and increased need for insulin in a diabetic have been reported. These have been rare reports of palpitation, dyspnea, and reversible loss of color vision.

OVERDOSAGE

Although doses up to 6000 mg/day have been given, no specific information is available on the management of acute massive overdosage. Should accidental overdosage occur, the stomach should be emptied by inducing emesis or by careful gastric lavage followed by the administration of activated charcoal.

Laboratory studies indicate that Ponstel should be absorbed from the gastrointestinal tract by activated charcoal. Vital functions should be monitored and supported. Because mefenamic acid and its metabolites are firmly bound to plasma proteins, hemodialysis and peritoneal dialysis may be of little value.

DOSAGE AND ADMINISTRATION

Administration is by the oral route, preferably with food.

The recommended regimen in acute pain for adults and children over 14 years of age is 500 mg as an initial dose followed by 250 mg every six hours as needed, usually not to exceed one week.

For the treatment of primary dysmenorrhea, the recommended dosage is 500 mg as an initial dose followed by 250 mg every six hours, starting with the onset of bleeding and associated symptoms. Clinical studies indicate that effective treatment can be initiated with the start of menses and should not be necessary for more than 2 to 3 days.

HOW SUPPLIED

N 0071-0540-24 (P-D 540) Ponstel (mefenamic acid) is available as 250 mg capsules in bottles of 100.

PARK-DAVIS

Div of Warner-Lambert Co

Morris Plains, NJ 07950 USA

0540G150

0540G150
Overview:
This supplement provides for revising the current Ponstel® labeling to comply with the current divisional class labeling for all NSAIDs.

Review:
Sponsor submitted revised draft labeling for the Ponstel® package insert identical to the proposed NSAID Package Insert Labeling Template with the following editorial changes:

- Line 76, “Special Populations” section, Pediatric: the tradename should be initially referenced.
- Lines 121-123, as proposed by Sponsor, two contraindications from current labeling were retained.
- Line 224, “Precautions” section, Renal Effects, the tradename should be referenced.
- Line 315-321, as proposed by Sponsor, retained from current labeling.
- Line 334, “Drug Interactions” Furosemide, the tradename should be referenced.
- Line 346, “If NSAIDs are administered...” should be re-worded to “During concomitant therapy with NSAIDs...”.
- Lines 357-364, As proposed by Sponsor, added Antacids and compounds that inhibit CYP2C9 to the “Drug Interaction” subsection.

Recommendation:
Approval. The Sponsor should be issued an approval letter.

Reviewer
D’Annie Gunter, P.D.

Medical Officer
Mordechai Averbach, M.D.
cc:
NDA 15-034/S-032
Divisional Files
HFD-550/Gunter/Koerner/Hyde
NDA 15-034/S-032

Parke-Davis Pharmaceutical Research
201 Tabor Road
Morris Plains, NJ 07950

Attention: James A. Parker, Jr.
Director, Worldwide Regulatory Affairs

Dear Ms. Carlson:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Ponstel ® (mefenamic acid) Capsules

NDA Number: 15-034

Supplement Number: S-032

Date of Supplement: January 19, 1998

Date of Receipt: January 20, 1998

Unless we find the application not acceptable for filing, this application will be filed under Section 505(b)(1) of the Act on March 21, 1998 in accordance with 21 CFR 314.101(a).

All communications concerning this NDA should be addressed as follows:

Food and Drug Administration
Division of Anti-Inflammatory, Analgesic and Ophthalmic Drug Products, HFD-550
Office of Drug Evaluation V
Center for Drug Evaluation and Research
Attention: Document Control Room
5600 Fishers Lane
Rockville, MD 20857

Sincerely,

Chin Koerner, M.S.
Acting Supervisory Consumer Safety Officer
Division of Anti-Inflammatory, Analgesic and Ophthalmic Drug Products, HFD-550
Office of Drug Evaluation V
Center for Drug Evaluation and Research